IL2 and neoplasm: WTX-124 is a novel systemically administered, tumor-selective IL-2 prodrug candidate consisting of a wild-type IL-2 cytokine tethered to an inactivation domain to prevent activation in nontarget tissue, a tumor protease-specific linker to allow activation in the TME and a half-life extension element to improve tumor exposure (73).